Madar Ahmed A, Stene Lars C, Meyer Haakon E, Brekke Mette, Lagerløv Per, Knutsen Kirsten V
Department of Community Medicine, Institute of Health and Society, University of Oslo, Oslo, Norway.
Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway.
Nutr J. 2016 Aug 9;15(1):74. doi: 10.1186/s12937-016-0192-7.
Both vitamin D and iron deficiencies are widespread globally, and a relationship between these deficiencies has been suggested. However, there is a paucity of randomised controlled trials assessing the effect of vitamin D supplementation on iron status.
We aimed to investigate whether 16 weeks of daily vitamin D3 supplementation had an effect on serum ferritin, haemoglobin, serum iron and transferrin saturation.
Overall, 251 participants from South Asia, Middle East and Africa aged 18-50 years who were living in Norway were randomised to receive daily oral supplementation of 10 μg vitamin D3, 25 μg vitamin D3, or placebo for 16 weeks during the late winter. Blood samples from baseline and after 16 weeks were analysed for serum 25-hydroxyvitamin D (s-25(OH) D), serum ferritin, haemoglobin and serum iron. In total, 214 eligible participants completed the intervention (86 % of those randomised). Linear regression analysis were used to test the effect of vitamin D3 supplementation combined (10 or 25 μg) and separate doses 10 or 25 μg compared to placebo on change (T2-T1) in each outcome variable adjusted for baseline s-25(OH)D values.
There was no difference in change in the levels of s-ferritin (1.9 μg/L, 95 % CI: -3.2, 7.0), haemoglobin (-0.02 g/dL, 95 % CI: -0.12, 0.09), s-iron (0.4 μg/L, 95 % CI: -0.5, 1.3) or transferrin saturation (0.7 %, 95 % CI: -0.6.1, 2.0) between those receiving vitamin D3 or those receiving placebo. Serum 25-hydroxyvitamin D increased from 29 nmol/L at baseline to 49 nmol/L after the intervention, with little change in the placebo group.
In this population of healthy ethnic minorities from South Asia, the Middle East and Africa who had low vitamin D status, 16 weeks of daily supplementation with 10 or 25 μg of vitamin D3 did not significantly affect the haemoglobin levels or other markers of iron status.
维生素D缺乏和铁缺乏在全球范围内都很普遍，且有人提出这两种缺乏之间存在关联。然而，评估补充维生素D对铁状态影响的随机对照试验较少。
我们旨在研究每日补充维生素D3 16周是否会对血清铁蛋白、血红蛋白、血清铁和转铁蛋白饱和度产生影响。
总体而言，251名年龄在18至50岁之间、生活在挪威的南亚、中东和非洲的参与者在冬末被随机分为三组，分别每日口服10μg维生素D3、25μg维生素D3或安慰剂，为期16周。分析基线和16周后的血样，检测血清25-羟基维生素D（s-25(OH)D）、血清铁蛋白、血红蛋白和血清铁。共有214名符合条件的参与者完成了干预（占随机分组者的86%）。采用线性回归分析，比较联合使用（10或25μg）和单独使用10或25μg维生素D3与安慰剂相比，在根据基线s-25(OH)D值调整后，各结局变量变化（T2-T1）的影响。
接受维生素D3组和接受安慰剂组在血清铁蛋白水平变化（1.9μg/L，95%CI：-3.2，7.0）、血红蛋白（-0.02g/dL，95%CI：-0.12，0.09）、血清铁（0.4μg/L，95%CI：-0.5，1.3）或转铁蛋白饱和度（0.7%，95%CI：-0.6，2.0）方面没有差异。干预后血清25-羟基维生素D从基线时的29nmol/L升至49nmol/L，安慰剂组变化不大。
在这群维生素D水平较低的南亚、中东和非洲健康少数族裔人群中，每日补充10或25μg维生素D3 16周对血红蛋白水平或其他铁状态指标没有显著影响。
Zotero 插件